Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Epetraborole

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights
    AN2 Therapeutics Reports Q2 2024 Results And Recent Highlights

    13 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240813783660/en

    BUSINESSWIRE
    13 Aug 2024
    Share Share
    AN2 Therapeutics shares fall after pausing lung disease study enrollment
    AN2 Therapeutics shares fall after pausing lung disease study enrollment

    13 Feb 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/an2-therapeutics-pause-lung-disease-study-enrollment-2024-02-12/

    REUTERS
    13 Feb 2024
    Share Share
    AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole
    AN2 Therapeutics commences Phase 2/3 Clinical Trial Evaluating Epetraborole

    13 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230913252729/en

    BUSINESSWIRE
    13 Sep 2023
    Share Share
    AN2 Therapeutics Initiates Pivotal PII/III Trial Evaluating Epetraborole
    AN2 Therapeutics Initiates Pivotal PII/III Trial Evaluating Epetraborole

    29 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/29/2471129/0/en/AN2-Therapeutics-Initiates-Pivotal-Phase-2-3-Trial-Evaluating-Epetraborole-for-Treatment-Refractory-MAC-Lung-Disease.html

    GLOBENEWSWIRE
    29 Jun 2022
    Share Share